Peter Sandercock

机构：University College London, University of Edinburgh · ORCID：0000-0001-8484-0135

发表论文 600 篇 · 总被引 54114 次 · h-index 107

代表论文

• Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021 · The Lancet · 被引 565)
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2022 · The Lancet · 被引 384)
• Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy (2021 · The Lancet · 被引 320)
• Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021 · The Lancet · 被引 292)
• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (2023 · The Lancet Diabetes & Endocrinology · 被引 118)
• Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial (2022 · Nephrology Dialysis Transplantation · 被引 110)